Literature DB >> 24509745

Setback for JAK2 inhibitors.

Mark Ratner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24509745     DOI： 10.1038/nbt0214-119a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Incyte comes of age with JAK inhibitor approval.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2013-01       Impact factor: 54.908
  2 in total
  6 in total

Review 1.  Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Authors:  Marcin Kortylewski; Dayson Moreira
Journal:  Cancer Immunol Immunother       Date:  2017-02-18       Impact factor: 6.968

2.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

3.  Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor.

Authors:  Kyoung Bin Yoon; Sung Yun Cho; Su Jin An; Kyeong Ryang Park; Hyo Jeong Lee; Hae Sung Yoon; Sun-Mi Lee; Yong-Chul Kim; Sun-Young Han
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

Review 4.  STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.

Authors:  Yu-Lin Su; Shuvomoy Banerjee; Seok Voon White; Marcin Kortylewski
Journal:  Int J Mol Sci       Date:  2018-06-19       Impact factor: 5.923

Review 5.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Authors:  Christopher Groth; Xiaoying Hu; Rebekka Weber; Viktor Fleming; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

6.  Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.

Authors:  Hanyang Lin; Min Chen; Katharina Rothe; Matthew V Lorenzi; Adrian Woolfson; Xiaoyan Jiang
Journal:  Oncotarget       Date:  2014-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.